Enzo Biochem (ENZ) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Enzo Biochem Reports Strong Fourth Quarter Results
October 13, 2015 7:30 AM EDTHigher Revenues and Operating Income, Plus Legal Settlements, Result in Net Income Exceeding $8 Million, or 18 Cents Per Share
NEW YORK--(BUSINESS WIRE)-- Enzo Biochem Inc. (NYSE: ENZ) today reported results for the fiscal quarter and year ended July 31, 2015.
Fourth Quarter Highlights
Revenues of $25.7 million were up 3% over the prior year quarter, despite decreased royalty income. Clinical Labs revenues of $17.2 million were up 11% over the same period in the prior year while Life Sciences product revenues were essentially unchanged on a constant... More